Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus NUTRACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus NUTRACORT.
ALA-SCALP vs NUTRACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Corticosteroid receptor agonist; induces anti-inflammatory proteins and suppresses inflammatory mediators.
Topical application of a 5% solution to the scalp twice daily.
One capsule (200 mg) orally twice daily with meals.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal half-life: 2-4 hours (mean 3 hours). Clinically, dosing every 6-8 hours maintains therapeutic levels.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal (primarily as glucuronide and sulfate conjugates, <10% unchanged) and fecal (biliary excretion of metabolites). Approximately 70-80% renal, 20-30% fecal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid